Evidence suggests benefits on weight and cardiometabolic risk
Dong H, Asmolovaite V, Farnaud S, Renshaw D
2 The development of and approval of new antihyperglycemic medications has favored the use of different pharmacological families with remarkable properties for the management of additional comorbidities such as renal disease, cardiovascular disease, and non-alcoholic fatty liver disease, that are highly prevalent in this subset
2021 study published in Pharmaceutics used physiologically-based pharmacokinetic (PBPK) modeling in pregnant women and found: Just before giving birth, the clearance level (CL) of acetaminophen via the toxic pathway was 1.8-fold higher than shortly after delivery
The company shared third-party lab test results with the FDA on July 21, 2026, which showed that samples from its Texas farms matched the outbreak strain, the FDA said